Imara Inc., is dedicated to developing novel therapeutics for patients with sickle cell disease. Despite years of research, we know treatment options are still very limited for patients with sickle cell disease (SCD). At Imara, they’re hoping to change that. Imara are developing a novel treatment called IMR-687. They believe IMR-687 has the possibility to reduce red blood cell sickling, red blood cell death and occlusion of blood vessels, while also reducing white blood cell stickiness.

Imara is conducting a Phase 2a clinical trial, evaluating escalating doses of IMR-687 in adult patients with sickle cell disease (SCD). IMR-687 has the potential to reduce red blood cell sickling, red blood cell death and the blockage of blood vessels that are the result of having sickle cell disease.  This randomized, double-blind, multi-center Phase 2a study of IMR-687 will evaluate the safety of increasing doses of IMR-687 as compared to placebo in adult patients with sickle cell disease.  The study will also examine blood levels of IMR-687, as well as explore the effects that IMR-687 has on the various blood measurements.

Approximately 54 patients will be enrolled at several clinical trial centers in the United Kingdom and the United States. Patients will undergo 6 months of treatment with IMR-687 and Imara anticipates completion of the study in 2019.

Here are a few important details about the enrollment criteria:

• The study is open to adult patients age 18-50 years old.
• Both patients who are not or are taking hydroxyurea (HU; also known as hydroxycarbamide) can participate in this study. Patients who are taking hydroxyurea must have been on a stable dose for at least 60 days prior to entering the screening process.
• Patients must also have stable kidney and liver function.

You can find more information about the clinical trial, including how to contact the study coordinators, on clinicaltrials.gov under the study ID number NCT03401112.

Currently Open Clinical Trial Locations:

Birmingham and Sandwell
Birmingham, United Kingdom
Contact: Elizabeth Green

Croydon University Hospital
Croydon, United Kingdom, CR7 7YE
Contact: Linda Sawyer

Darent Valley Hospital
Dartford, United Kingdom, DA2 8DA

Whittington Hospital
London, United Kingdom, N19 5NF

University College Hospital (UCLH)
London, United Kingdom, NW1 2BU
Contact: Alyna Sheikh
Principal Investigator: Perla Elefjeriou

University Hospital Lewisham
London, United Kingdom, SE13 6LH

Kings College Hospital
London, United Kingdom, SE5 9RS

Guy’s and St Thomas Hospital
London, United Kingdom
Contact: Yemi Adelaja

Homerton Hospital
London, United Kingdom
Contact: Anna Price